Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HOUSTON, TX / ACCESS NEWSWIRE / SEPTEMBER 3, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THAT IT WILL PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE BEING HELD SEPTEMBER 8-10, 2025 IN NEW YORK, NY.

CNS PHARMACEUTICALS TO PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

STRONG CASH POSITION OF $12.1 MILLION EXPECTED TO FUND OPERATIONS INTO THE SECOND HALF OF 2026 DRIVING LEAD PROGRAM, TPI 287, TOWARDS PHASE 2 STUDY FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) HOUSTON, TX / ACCESS NEWSWIRE / AUGUST 15, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND PROVIDED A CORPORATE UPDATE. "EVERY DECISION WE MAKE IS GROUNDED IN OUR SCIENCE AND DRIVEN BY A SENSE OF URGENCY AND RESPONSIBILITY TO THE PATIENTS AND FAMILIES COUNTING ON US FOR BETTER OUTCOMES.

CNS PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- LIVE VIDEO WEBCAST ON TUESDAY, AUGUST 19TH AT 2:40 PM ET HOUSTON, TX / ACCESS NEWSWIRE / AUGUST 14, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THAT IT WILL PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH BEING HELD VIRTUALLY AUGUST 19-21, 2025 DETAILS FOR THE PRESENTATION ARE AS FOLLOWS: DATE AND TIME: TUESDAY, AUGUST 19, 2025 AT 2:40 PM ET PRESENTER: JOHN CLIMACO, CHIEF EXECUTIVE OFFICER REGISTRATION LINK: HERE ABOUT WEBULL FINANCIAL WEBULL FINANCIAL IS A LEADING ONLINE BROKERAGE PLATFORM COMMITTED TO EMPOWERING SELF-DIRECTED INVESTORS WITH INNOVATIVE TOOLS AND CUTTING-EDGE TECHNOLOGY. WITH LOW-COST TRADING ON A WIDE RANGE OF ASSETS, ADVANCED CHARTING TOOLS, AND REAL-TIME MARKET DATA, WEBULL IS REVOLUTIONIZING THE WAY INDIVIDUALS APPROACH INVESTING.

CNS PHARMACEUTICALS TO PRESENT AT THE WEBULL FINANCIAL CORPORATE CONNECT WEBINAR SERIES: BIOTECH/MEDTECH

 VIDEO WEBCAST NOW AVAILABLE ON-DEMAND HOUSTON, TX / ACCESS NEWSWIRE / JULY 22, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THAT JOHN CLIMACO, CHIEF EXECUTIVE OFFICER OF CNS PHARMACEUTICALS, PARTICIPATED IN THE VIRTUAL INVESTOR "WHAT'S YOUR STORY" SUMMER SPOTLIGHT ON-DEMAND CONFERENCE. AS PART OF THE EVENT, MR.

CNS PHARMACEUTICALS TO PARTICIPATE IN THE VIRTUAL INVESTOR "WHAT'S YOUR STORY" SUMMER SPOTLIGHT ON-DEMAND CONFERENCE

HOUSTON, TX / ACCESS NEWSWIRE / JULY 18, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED A 1-FOR-12 REVERSE SPLIT OF ITS COMMON STOCK. BEGINNING ON JULY 22, 2025, THE COMPANY'S COMMON STOCK WILL CONTINUE TO TRADE ON THE NASDAQ CAPITAL MARKET ("NASDAQ") ON A SPLIT ADJUSTED BASIS UNDER THE TRADING SYMBOL "CNSP" BUT WILL TRADE UNDER THE FOLLOWING NEW CUSIP NUMBER: 18978H508.

CNS PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT

HOUSTON, TX / ACCESS NEWSWIRE / JULY 9, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THAT JOHN CLIMACO, CEO OF CNS PHARMACEUTICALS RECENTLY PARTICIPATED IN A VIRTUAL INVESTOR CEO CONNECT SEGMENT. AS PART OF THIS SEGMENT, MR.

CNS PHARMACEUTICALS PARTICIPATES IN VIRTUAL INVESTOR CEO CONNECT SEGMENT

MODERATED DISCUSSION WITH FOUNDING PHYSICIAN OF THE BRAIN TUMOR CENTER AND DIRECTOR OF NEURO-ONCOLOGY AT PIEDMONT ATLANTA HOSPITAL, DR. ERIN DUNBAR HOUSTON, TX / ACCESS NEWSWIRE / JUNE 24, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THE RELEASE OF A VIRTUAL INVESTOR KOL CONNECT SEGMENT FEATURING DR. ERIN DUNBAR, A FOUNDING PHYSICIAN OF THE BRAIN TUMOR CENTER AND DIRECTOR OF NEURO-ONCOLOGY AT PIEDMONT ATLANTA HOSPITAL, WHO SPECIALIZES IN THE COMPREHENSIVE CARE OF BRAIN AND SPINE TUMOR PATIENTS WHO ARE BATTLING BOTH PRIMARY AND METASTATIC TUMORS. AS PART OF THE SEGMENT, DR. DUNBAR DISCUSSED THE PATIENT JOURNEY AND CURRENT TREATMENT LANDSCAPE FOR GLIOBLASTOMA MULTIFORME AND CNS PHARMA'S LEAD PRODUCT CANDIDATE, TPI 287, AND ITS POTENTIAL AS A TREATMENT FOR GBM AS WELL AS FOR FUTURE INDICATIONS IN METASTATIC TUMORS.

CNS PHARMACEUTICALS ANNOUNCES VIRTUAL INVESTOR KOL CONNECT SEGMENT DISCUSSING GLIOBLASTOMA MULTIFORME (GBM) AND LEAD PRODUCT CANDIDATE TPI 287

IN PERSON PRESENTATION TODAY, THURSDAY, JUNE 5TH AT 9:30 AM ET TO DISCUSS COMPANY'S LEAD PROGRAM, TPI 287, IN DEVELOPMENT FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) HOUSTON, TX / ACCESS NEWSWIRE / JUNE 5, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THAT SANDRA SILBERMAN, M.D., PH.D., CHIEF MEDICAL OFFICER OF CNS PHARMACEUTICALS, WILL PRESENT AT THE LENOX HILL HOSPITAL, DEPARTMENT OF NEUROSURGERY'S BRAIN TUMOR BIOTECH SUMMIT BEING HELD ON JUNE 5, 2025 IN NEW YORK, NY.

CNS PHARMACEUTICALS' CHIEF MEDICAL OFFICER, SANDRA SILBERMAN, MD, PHD TO PRESENT AT THE 2025 BRAIN TUMOR BIOTECH SUMMIT

CASH EXPECTED TO FUND OPERATIONS INTO THE SECOND HALF OF 2026 ADVANCING DEVELOPMENT STRATEGY FOR LEAD PROGRAM TPI 287 TO COMMENCE PHASE 2 STUDY AROUND YEAR END 2025 FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) HOUSTON, TX / ACCESS NEWSWIRE / MAY 16, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDED A CORPORATE UPDATE. "OUR COMPANY REMAINS FOCUSED AS TIGHTLY AS EVER ON NEURO-ONCOLOGY DRUG DEVELOPMENT.

CNS PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

HOUSTON, TX / ACCESS NEWSWIRE / MAY 13, 2025 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THE PRICING OF ITS "REASONABLE BEST EFFORTS" PUBLIC OFFERING WITH A SINGLE HEALTHCARE FOCUSED INSTITUTIONAL INVESTOR FOR THE PURCHASE AND SALE OF 3,952,570 SHARES OF COMMON STOCK OF THE COMPANY (THE "COMMON STOCK) (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF), AT A PURCHASE PRICE OF $1.265 PER SHARE OF COMMON STOCK. THE COMPANY FURTHER AGREED TO ISSUE TO THE INVESTORS SERIES F COMMON STOCK PURCHASE WARRANTS TO PURCHASE UP TO 3,952,570 SHARES OF COMMON STOCK (THE "SERIES F WARRANTS").

CNS Pharmaceuticals, Inc.

CNSP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CNS Pharmaceuticals, Inc.

CNSP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CNSP